Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Exclusive: Ernst, audit clients cut lobbying ties-records

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 07:11am CET
Entrances to the offices of Ernst & Young is seen in New York

WASHINGTON/NEW YORK (Reuters) - Ernst & Young's lobbying unit is no longer listed as a lobbyist for three major U.S. companies, all of whom were 2011 audit clients of the accounting giant. The deregistration follows questions raised by two U.S. senators in March about whether the dual relationships crossed auditor independence boundaries.

Documents filed last month with Congress showed that Washington Council Ernst & Young, the E&Y unit, was no longer registered as doing lobbying work for Amgen Inc (>> Amgen, Inc.), CVS Caremark Corp (>> CVS Caremark Corporation) and Verizon Communications Inc (>> Verizon Communications Inc.).

A lobbying-contract termination was also filed on March 31 for a fourth company, Nomura Holdings Inc (>> Nomura Holdings Inc.), which, according to securities filings, uses an E&Y affiliate for auditing services. E&Y had provided lobbying services to Nomura since June 2011, according papers on file with Congress.

Auditors that review corporations' books every year must follow rules limiting other ties with audit clients. The rules - meant to prevent auditors from getting too cozy with audit clients - were substantially beefed up a decade ago after a rash of accounting scandals at Enron Corp. and other companies.

An Ernst & Young spokesman declined to comment on the discontinued lobbying relationships. Officials with Nomura, Verizon and CVS declined to comment. Amgen officials could not immediately be reached for comment.

The chief accountant for the U.S. Securities and Exchange Commission, James Kroeker, speaking at a financial reporting conference at Baruch College in New York on Thursday, said SEC rules state an auditor should not act in an advocacy role for a company it audits and lobbying would be inconsistent with that.

Kroeker did not mention any audit firms by name.

He said: "If you think about lobbying in the traditional sense, you would say, 'wouldn't somebody that's lobbying be placing themselves in a position to be an advocate?'"

Asked whether the SEC was looking into E&Y's lobbying activities, an official in the agency's enforcement division declined to comment because its investigations are not public.

"We are aware of it and we are cognizant of what the rules are," said Howard Scheck, chief accountant of the SEC's division of enforcement, on the sidelines of Thursday's conference.

"If there's a violation that we find, we'll certainly do something about that," he said, without referring to E&Y.

Reuters reported in March that Washington Council Ernst & Young had been hired as a lobbyist for a number of E&Y's audit clients, prompting two lawmakers to demand closer scrutiny.

Democratic senators Carl Levin and Jack Reed both expressed concerns at the time and urged the SEC to look into the matter. On Thursday, Reed's office did not immediately respond to inquiries seeking comment. Levin's office declined to comment.

Verizon had a particularly long relationship with E&Y's lobbyists, who helped the telecommunications company with tax issues beginning in September 2001. The two other lobbying relationships were more recent, dating to February in the case of Amgen and September in the case of CVS Caremark. Both contracts were connected to corporate tax debates. The three U.S. terminations were all effective March 31 and Nomura's termination was filed the same day.

The E&Y spokesman referred Reuters to its earlier statement that Washington Council's work complied with independence rules.

The work was approved by clients' audit committees and it was limited to tax-related issues, E&Y spokesman Charles Perkins said when Reuters reported on the issue in March.

Washington Council did not solicit votes on legislation for E&Y audit clients, Perkins said.

The Public Company Accounting Oversight Board, the watchdog for U.S. auditors, is looking to shore up independence rules after finding numerous instances in which auditors did not dig deeply enough to challenge clients' financial numbers.

The SEC's Kroeker said he was encouraged to see the board tackling the subject.

"Independence is really the bedrock, the foundation of the value that's provided by a third-party audit," he said.

(Reporting by Dena Aubin and David Ingram; Additional reporting by Kim Dixon; Editing by Kevin Drawbaugh and Matt Driskill)

By David Ingram and Dena Aubin

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN 1.81% 185.62 Delayed Quote.4.91%
CVS HEALTH 0.10% 68.01 Delayed Quote.-5.16%
NOMURA HOLDINGS INC 1.52% 656 End-of-day quote.-3.09%
VERIZON COMMUNICATIONS 0.75% 48.2 Delayed Quote.-9.39%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
07:29aCVS HEALTH : Antitrust Subcommittee to Hold Hearing on CVS-Aetna Merger
AQ
02/22CVS HEALTH : House Judiciary Committee - Hearing
AQ
02/22CVS HEALTH : House Judiciary Committee News Release
AQ
02/21Albertsons to buy Rite Aid as Amazon threat looms
RE
02/20CVS HEALTH : Fast Company Recognizes CVS Health on 2018 World's Most Innovative ..
PR
02/15CVS HEALTH : Management's Discussion and Analysis of Financial Condition and Res..
AQ
02/14CVS HEALTH : increasing starting pay to $11 an hour
AQ
02/12CVS HEALTH : latest to boost pay, programs thanks to federal tax reform
AQ
02/10CVS HEALTH : Salisbury town center CVS sold for $7.9 million
AQ
02/10CVS HEALTH : CEO Reveals How It Will Benefit From Tax Reform
AQ
More news
News from SeekingAlpha
03:18pFans Of CVS-Aetna Deal Should Enter Via Aetna Shares 
02/22IRA Portfolio 1 Year Buying-Selling Update And Now 5.8% Dividend Yield 
02/22RITE AID : The Nail In The Coffin 
02/22ACETO : Collapsing Generic Drug Pricing Brings Risk Of Covenant Violations 
02/22RITE AID : Better To Stay Away 
Financials ($)
Sales 2018 189 B
EBIT 2018 9 905 M
Net income 2018 5 768 M
Debt 2018 20 750 M
Yield 2018 3,26%
P/E ratio 2018 12,25
P/E ratio 2019 11,24
EV / Sales 2018 0,48x
EV / Sales 2019 0,45x
Capitalization 69 653 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 88,1 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-5.16%69 653
WALGREENS BOOTS ALLIANCE-4.12%68 980
EXPRESS SCRIPTS HOLDING CO1.59%42 948
MCKESSON CORPORATION-4.08%31 186
CARDINAL HEALTH12.31%21 655
AMERISOURCEBERGEN7.35%21 653